Skip to main content
SpringerLink
Log in

Are There Alternative Chemotherapy Regimens for EXTREME in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN)?

  • Chapter
  • First Online:
Critical Issues in Head and Neck Oncology

  • 422 Accesses

Abstract

The EXTREME regimen is the gold-standard treatment in the first-line setting for R/M SCCHN patients. New approaches have explored taxane, platinum and cetuximab-based combinations and results of TPExtreme trial are eagerly awaited. There is also an urgent need to explore these new combinations with emerging immunotherapies in the first-line setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6.

    Article  Google Scholar 

  2. Argiris A, Harrington KJ, Tahara M, et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2017;7:72.

    Article  Google Scholar 

  3. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  CAS  Google Scholar 

  4. Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26(9):1941–7.

    Article  CAS  Google Scholar 

  5. TPExtreme. https://www.clinicaltrials.gov/ct2/show/NCT02268695?term=NCT02268695&rank=1.

  6. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

    Article  Google Scholar 

  7. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.

    Article  CAS  Google Scholar 

  8. Cohen EE, Harrington KJ, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol. 2017;28(suppl_5):v605–49. https://doi.org/10.1093/annonc/mdx440.

    Article  Google Scholar 

  9. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245–51.

    Article  CAS  Google Scholar 

  10. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257–63.

    Article  CAS  Google Scholar 

  11. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–6.

    Article  CAS  Google Scholar 

  12. ELAN-FIT. https://www.clinicaltrials.gov/ct2/show/NCT01864772?term=elan+fit&rank=1.

  13. Vermorken JB, Remenar E, Hitt R, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol. 2014;32(5s)(abstr # 6021).

    Google Scholar 

  14. Guigay J, Peyrade F, Petre Lazar B, et al. Cetuximab relative dose intensity in recurrent/metastatic squamous cell carcinoma of the head and neck: first observational prospective study in unselected patients (DIRECT study). Ann Oncol. 2014;25(suppl_4):iv340–56.

    Article  Google Scholar 

  15. Le Tourneau CL, Ghiani M, Cau MC, et al. The observational ENCORE study: cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Ann Oncol. 2017;28(Suppl 28):v372–94.

    Google Scholar 

  16. Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34(4):1531–5.

    CAS  PubMed  Google Scholar 

  17. ELAN UNFIT. https://www.clinicaltrials.gov/ct2/show/NCT01884623?term=elan&rank=6.

  18. Vermorken JB, Licitra L, Stöhlmacher-Williams J, et al. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2013;49(13):2877–83.

    Article  CAS  Google Scholar 

  19. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.

    Article  CAS  Google Scholar 

  20. Vermorken JB, Peyrade F, Krauss J, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014;25(3):682–8.

    Article  CAS  Google Scholar 

  21. Machiels JP, Kaminsky MC, Keller U, et al. Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Investig New Drugs. 2013;31(5):1207–16.

    Article  CAS  Google Scholar 

  22. Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016–22.

    Article  CAS  Google Scholar 

  23. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(Suppl 4):iv61–8.

    Article  Google Scholar 

  24. Rose WC, Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res. 2004;10(21):7413–7.

    Article  CAS  Google Scholar 

  25. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536–5.

    Article  CAS  Google Scholar 

  26. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562–7.

    Article  CAS  Google Scholar 

  27. Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;29:1004–9.

    Article  CAS  Google Scholar 

  28. Bossi P, Miceli R, Locati LD, et al. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2017;28(11):2820–6.

    Article  CAS  Google Scholar 

  29. Friesland S, Tsakonas G, Kristensen C, et al. Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial). J Clin Oncol. 2018;36(suppl; abstr 6032).

    Article  Google Scholar 

  30. Guigay J, Even C, Mayache-Badis L, et al. Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance. Oral Oncol. 2017;68:114–8.

    Article  CAS  Google Scholar 

  31. Even C, Bobillot B, Mayache-Badis L, et al. Results of TPEx (docetaxel, cisplatin, cetuximab) regimen use in first-line with recurrent and/or metastatic squamous cell carcinoma of the head and neck in a single institution. Ann Oncol. 2014;25(suppl_4):iv340–56. https://doi.org/10.1093/annonc/mdu340.

    Article  Google Scholar 

  32. Adkins D, Ley J, Atiq O, et al. Multicenter phase 2 trial of cis/carboplatin, nanoparticle albumin bound (nab)-paclitaxel, and CeTUXimabas (CACTUX) as first line therapy for recurrent/metastatic head and neck squamous cell carcinoma ASTRO. 2018. https://doi.org/10.1016/j.ijrobp.2017.12.029.

    Article  Google Scholar 

  33. American Academy of Allergy, Asthma & Immunology. A new approach to taxane-induced hypersensitivity reactions. https://www.aaaai.org/global/latest-research-summaries/Current-JACI-Research/taxane-induced-hypersensitivity. 2015. Accessed 03/02 2018.

  34. Boulanger J, Boursiquot J, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014;21(4):e630–41.

    Article  Google Scholar 

  35. Scripture C, Figg W, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4(2):165–72.

    Article  CAS  Google Scholar 

  36. Argiris A, Li S, Savvides P, et al. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. J Clin Oncol. 2017;35(15_suppl):6000.

    Article  Google Scholar 

  37. Wirth LJ, Dakhil S, Kornek G, et al. PARTNER: an open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016;61:31–40.

    Article  CAS  Google Scholar 

  38. William WN, Feng L, Kies MS, et al. Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). J Clin Oncol. 2017;35(suppl 15):6017A.

    Article  Google Scholar 

  39. Posch D, Fuchs H, Kornek G, et al. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. Sci Rep. 2016;6:32946.

    Article  CAS  Google Scholar 

  40. Bernad IP, Trufero JM, Urquizu LC, et al. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors. Clin Transl Oncol. 2017;19(6):769–76.

    Article  CAS  Google Scholar 

  41. Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813–23.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center Antoine-Lacassagne, FHU Oncoage, Université Côte d’Azur, Nice, France

    Joël Guigay

Authors
  1. Joël Guigay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joël Guigay .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

    Jan B. Vermorken

  2. Department of Radiation Oncology, Charité University Medicine, Berlin, Germany

    Volker Budach

  3. Department of Otolaryngology , VU University Medical Center, Amsterdam, The Netherlands

    C. René Leemans

  4. Institut Roi Albert II, Université Catholique de Louvain , Louvain-la-Neuve, Belgium

    Jean-Pascal Machiels

  5. Department of Otorhinolarynology, University of Brescia, Brescia, Italy

    Piero Nicolai

  6. Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

    Brian O'Sullivan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Guigay, J. (2018). Are There Alternative Chemotherapy Regimens for EXTREME in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN)?. In: Vermorken, J., Budach, V., Leemans, C., Machiels, JP., Nicolai, P., O'Sullivan, B. (eds) Critical Issues in Head and Neck Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-98854-2_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98854-2_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98853-5

  • Online ISBN: 978-3-319-98854-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation